Hologic Stock Falls After Q3 Revenue Dip, But It Lifts Revenue and Profit Outlook

Hologic Inc HOLX posted Q3 adjusted EPS of $0.93, down from $0.95 a year ago and beating the consensus of $0.88.

Revenue of $984.4 million decreased 1.8% Y/Y (down 1.6% on constant currency), driven by lower sales of COVID-19 assays compared to the prior year period, as expected, exceeded the company's prior guidance of $930-$980 million and the consensus of $957.13 million.

Diagnostics sales dipped by 21.5% but, excluding COVID-19-related products, grew by 11.8% on an organic, constant currency basis.

Breast Health revenue increased 27.4%, primarily due to higher capital equipment revenue than the prior year period, as an improving semiconductor chip supply environment enabled more gantry deliveries.

Surgical revenue grew 13.9%, primarily driven by results from the company's hysteroscopic portfolio.

Non-GAAP gross margin of 60.8% decreased (250) basis points, while Non-GAAP operating margin of 28.9% decreased (340) basis points.

Guidance: For FY23, Hologic projects revenue of $3.995 - $4.035 billion, compared to $3.925-$4.025 expected earlier and the consensus of $4.02 billion.

It expects adjusted EPS of $3.87-$3.94 versus the consensus of $3.91 and earlier guidance of $3.75-$3.95.

For Q4 FY23, Hologic sees revenues of $910-$950 million and adjusted EPS of $0.80-$0.87 compared to the consensus of $951.07 million and $0.87, respectively.

Price Action: HOLX shares are down 3.27% at $76.82 on the last check Tuesday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsLarge CapNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!